Insights, Delivered Daily.

From breaking market trends to long-term strategy tips, we bring you curated financial content—designed to inform, educate, and empower.
Subscribe to our Newsletter

Daily Market Note (165)

Daily Market Note | Siebert Financial Corporation (“Siebert”) has a full range of brokerage and financial advisory services offered through its operating subsidiaries, affiliates and brands associated with Siebert Financial described below (165)

Daily Market Note

Almost Cooked

Almost cooked. Stocks rallied yesterday as Congressional leaders appeared to zero in on a stimulus package. Motivation on both sides of the isle sparked a broad-based rally in stocks.
Read More
Daily Market Note

By A Thread

By a thread. Stocks struggled to hold on to early gains as the Senate continued to flounder on fiscal relief. Healthcare workers are getting vaccinated and the US national death toll passed another ugly milestone, leaving investors on edge.
Read More
Daily Market Note

Watching The Wheels Go 'Round and 'Round

Watching the wheels go ‘round and ‘round. Stocks closed out a losing week in the red as lawmakers could not agree on the much-needed, yet highly elusive economic stimulus package. Sentiment is rising, according to the latest U of M survey - we like that.
Read More
Daily Market Note

Direction Lost

Direction lost. Stocks slipped yesterday after poor economic numbers and more dissent in Washington. Airbnb’s IPO day pop was a good distraction on a day with very little positive news.
Read More
Daily Market Note

Rudderless

Rudderless. Stocks struggled to find direction yesterday with the vaccine not quite there yet and the expected stimulus… not quite there yet. Investors took the opportunity to rethink the benefits of growth stocks as money-losing mega-unicorn IPO rises +85% on its first day on the exchange.
Read More
Daily Market Note

Anti Body

Anti body. Stocks rose moderately yesterday as investors cling to hope that a stimulus package may come soon. The first wave of vaccinations have started in the UK and the US FDA is in favor of approval for Pfizer’s vaccine, expected within days.
Read More